Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 14/20 | 0.60 |
| ▸ | NPY4R | P50391 | 7/20 | 0.60 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.60 |
| ▸ | NPY1R | P25929 | 5/20 | 0.60 |
| ▸ | RAMP3 | O60896 | 3/20 | 0.60 |
| ▸ | CALCR | P30988 | 3/20 | 0.60 |
| ▸ | TFPI | P10646 | 2/20 | 0.58 |
| ▸ | INSR | P06213 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Elcitonin SCHEMBL29380850 | 0.97 | NPY2R (0.60) | NPY2RNPY4RNPY5RNPY1RRAMP3 | |
| SCHEMBL30888738 | 0.94 | NPY2R (0.63) | NPY2RNPY4RNPY5RNPY1RRAMP3 | |
| Calcitonin Salmon SCHEMBL29392873 | 0.92 | INSR (0.64) | NPY2RNPY4RNPY5RNPY1RRAMP3 | |
| Calcitonin Salmon SCHEMBL269785 | 0.92 | INSR (0.64) | NPY2RNPY4RNPY5RNPY1RRAMP3 | |
| Elcatonin SCHEMBL29361233 | 0.90 | CALCR (0.64) | NPY2RNPY4RNPY5RNPY1RRAMP3 | |
| Elcatonin SCHEMBL30495930 | 0.90 | CALCR (0.64) | NPY2RNPY4RNPY5RNPY1RRAMP3 | |
| SCHEMBL29500562 | 0.88 | CALCR (0.68) | NPY2RRAMP3CALCRINSR | |
| Calcitonin Salmon SCHEMBL29360745 | 0.86 | CALCR (0.69) | NPY2RRAMP3CALCRINSR | |
| SCHEMBL268329 | 0.84 | NPY2R (0.73) | NPY2RNPY4RNPY5RNPY1RRAMP3 | |
| SCHEMBL29388398 | 0.84 | NPY2R (0.75) | NPY2RNPY4RNPY5RNPY1RRAMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137844-A1 | MEDICAL DEVICE AND METHOD FOR MANUFACTURING THE SAME | TERUMO KABUSHIKI KAISHA (JP) | 2026-05-21 | — | — | US | disclosed |
| EP-4740974-A1 | MEDICAL INSTRUMENT AND MANUFACTURING METHOD THEREFOR | Terumo Kabushiki Kaisha (JP) | 2026-05-13 | — | — | EP | disclosed |
| US-12595284-B2 | Amatoxin antibody-drug conjugates and uses thereof | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2026-04-07 | — | — | US | disclosed |
| US-20260078148-A1 | AMATOXIN ANTIBODY-DRUG CONJUGATES AND USES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2026-03-19 | — | — | US | disclosed |
| US-20260014202-A1 | THERAPEUTIC METHODS USING ANTIBODY DRUG CONJUGATES (ADCS) | REGENERON PHARMACEUTICALS, INC. | 2026-01-15 | — | — | US | disclosed |
| WO-2025018283-A1 | MEDICAL INSTRUMENT AND MANUFACTURING METHOD THEREFOR | テルモ株式会社 | 2025-01-23 | — | — | WO | disclosed |
| CN-118459534-A | Protopanaxadiol derivative and synthesis and application thereof | 华东师范大学 | 2024-08-09 | — | — | CN | disclosed |
| EP-2716164-B2 | ADDITIVE AND METHOD FOR PRODUCING OIL-IN-WATER EMULSIFIED FOOD PRODUCT COMPOSITION | KANEKA CORP (JP) | 2024-06-12 | — | — | EP | disclosed |
| EP-3378324-B1 | METHOD FOR PRODUCING OIL-IN-WATER EMULSIFIED FOOD PRODUCT COMPOSITION | KANEKA CORP (JP) | 2023-05-10 | — | — | EP | disclosed |
| US-20230135930-A1 | AMATOXIN ANTIBODY-DRUG CONJUGATES AND USES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2023-05-04 | — | — | US | disclosed |
| CN-1091314-A | The pharmaceutical composition that contains calcitonin | SMITHKLINE BEECHAM FARMA (IT) | 1994-08-31 | — | — | CN | disclosed |
| EP-0607229-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A CALCITONIN, A GLYCYRRHIZINATE AS ABSORPTION ENHANCER AND BENZYL | Smithkline Beecham Farmaceutici S.p.A. (IT) | 1994-07-27 | — | — | EP | disclosed |
| WO-1994008622-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A CALCITONIN | SMITHKLINE BEECHAM FARMACEUTICI S.P.A. (IT) | 1994-04-28 | — | — | WO | disclosed |
| EP-0327756-B1 | Pharmaceutical compositions comprising a calcitonin and a glycyrrhizinate as absorption enhancer | SMITHKLINE BEECHAM FARMA (IT) | 1994-01-26 | — | — | EP | disclosed |
| WO-1993006854-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A CALCITONIN, A GLYCYRRHIZINATE AS ABSORPTION ENHANCER AND BENZYL | SMITHKLINE BEECHAM FARMACEUTICI S.P.A. (IT) | 1993-04-15 | — | — | WO | disclosed |
| EP-0526524-A1 | PHARMACEUTICAL COMPOSITIONS. | SMITH KLINE FRENCH LAB (GB) | 1993-02-10 | — | — | EP | disclosed |
| US-5183802-A | Mixed with nontoxic effective amount of adsorption enhancer-ammonium glycyrrhizinate and a carrier; used as nose sprays for treatment of osteoporosis | ISF SOCIETA PER AZIONI (IT) | 1993-02-02 | — | — | US | disclosed |
| WO-1991016041-A1 | PHARMACEUTICAL COMPOSITIONS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1991-10-31 | — | — | WO | disclosed |
| EP-0327756-A2 | Pharmaceutical compositions comprising a calcitonin and a glycyrrhizinate as absorption enhancer | Smithkline Beecham Farmaceutici S.p.A. (IT) | 1989-08-16 | — | — | EP | disclosed |
| CN-1033568-A | New calcitonin compositions and the method for making thereof of containing | ISF SPA (IT) | 1989-07-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135930-A1 | AMATOXIN ANTIBODY-DRUG CONJUGATES AND USES THEREOF | MYADM, FUT7, SIGLEC7 | NPY2R 4610/4885NPY4R 4608/4885NPY5R 4102/4885 |
| US-12595284-B2 | Amatoxin antibody-drug conjugates and uses thereof | HLA-DRB1, CD2, CD74 | NPY2R 4160/4885NPY4R 4488/4885NPY5R 2423/4885 |
| US-20260137844-A1 | MEDICAL DEVICE AND METHOD FOR MANUFACTURING THE SAME | F2, FGB, F9 | NPY2R 1099/4885NPY4R 2387/4885NPY5R 1840/4885 |
| US-20260014202-A1 | THERAPEUTIC METHODS USING ANTIBODY DRUG CONJUGATES (ADCS) | CD2, MYADM, CD47 | NPY2R 2933/4885NPY4R 3584/4885NPY5R 2178/4885 |
| US-20260078148-A1 | AMATOXIN ANTIBODY-DRUG CONJUGATES AND USES THEREOF | CD2, CD74, CD99 | NPY2R 3131/4885NPY4R 4060/4885NPY5R 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.